<div id="readability-page-1"><div>By Jason Chau Shares of Sino Biopharmaceutical jumped after the Chinese pharma major said it plans to acquire Hangzhou Hygieia Biomedical. The stock rose as much as 5.5% on Wednesday morning in Hong Kong, and was last up 4.1%. Sino Biopharm said in a Tuesday filing that it plans to acquire Hygeia for up to 1.2 billion Chinese yuan, equivalent to US$172 million, in cash and stock. Hygieia is a Chinese startup specializing in the research and development of innovative drugs that use small interfering ribonucleic acids, or siRNA, technology, with a strategic focus on chronic disease areas covering weight management, cardiovascular diseases and neurological disorders. Sino Biopharm said the acquisition will accelerate the group's innovation initiatives and clinical advancement in chronic disease treatment, which it is positioning as a new growth engine. The deal, which follows Sino Biopharm's acquisition of cancer-treatment specialist LaNova Medicines last year, &#34;reflect[s] the company's deep pockets and determination to enrich its research pipeline non-organically,&#34; Nomura analyst Jialin Zhang said in a note. The 1.2 billion yuan offer is a good deal for Sino Biopharm, he added. China's healthcare companies have made notable advances in innovation lately, attracting strong interest from investors and global pharma majors, which have entered into a series of licensing deals for Chinese innovative drugs. The Hang Seng Biotech Index is up over 17% so far this year, outpacing the broader Hang Seng Index's 5.5% gain. Write to Jason Chau at jason.chau@wsj.com (END) Dow Jones Newswires01-14-26 0101ET</div></div>

中國生物制藥

中國生物製藥的股價在宣佈計劃以高達 12 億元人民幣（約合 1.72 億美元）收購杭州海吉亞生物醫學後上漲了 5.5%。此次收購旨在增強中國生物製藥在慢性疾病治療方面的創新能力，將其定位為新的增長引擎。分析師對這筆交易持積極態度，強調中國生物製藥致力於擴展其研究管道。中國醫療保健行業經歷了顯著的創新，吸引了全球製藥公司的關注，恒生生物科技指數今年上漲超過 17%

中國生物製藥計劃收購 Hygieia 後，股價大幅上漲